Press Releases 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
23.25 ^USD	-1.19%		-7.92%	+14.76%

Apr. 15	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
Apr. 15	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	Mar. 28	GL
4DMT to Participate in Upcoming Investor Conferences	Mar. 04	GL
4DMT Reports Full Year 2023 Financial Results and Operational Highlights	Feb. 29	GL
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024	Feb. 12	GL
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024	Feb. 12	AQ
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock	Feb. 06	GL
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock	Feb. 05	GL
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock	Feb. 05	AQ
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD	Feb. 03	AQ
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD	Feb. 03	GL
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden	Jan. 29	GL
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden	Jan. 29	AQ
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease	Jan. 23	GL
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease	Jan. 23	AQ
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates	Jan. 04	AQ
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates	Jan. 04	GL
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases	Jan. 03	GL
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases	Jan. 03	AQ
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD	Dec. 21	GL
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD	Dec. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Press Releases

Filters